Department of Neurological Surgery, University of California, San Francisco, USA.
Neuro Oncol. 2023 Dec 8;25(12):2117-2133. doi: 10.1093/neuonc/noad133.
After recent updates to the World Health Organization pathological criteria for diagnosing and grading diffuse gliomas, all major North American and European neuro-oncology societies recommend a maximal safe resection as the initial management of a diffuse glioma. For neurosurgeons to achieve this goal, the surgical plan for both low- and high-grade gliomas should be to perform a supramaximal resection when feasible based on preoperative imaging and the patient's performance status, utilizing every intraoperative adjunct to minimize postoperative neurological deficits. While the surgical approach and technique can vary, every effort must be taken to identify and preserve functional cortical and subcortical regions. In this summary statement on the current state of the field, we describe the tools and technologies that facilitate the safe removal of diffuse gliomas and highlight intraoperative and postoperative management strategies to minimize complications for these patients. Moreover, we discuss how surgical resections can go beyond cytoreduction by facilitating biological discoveries and improving the local delivery of adjuvant chemo- and radiotherapies.
在世界卫生组织最近更新了用于诊断和分级弥漫性神经胶质瘤的病理学标准后,北美和欧洲的主要神经肿瘤学会都建议将最大限度安全切除作为弥漫性神经胶质瘤的初始治疗方法。为了实现这一目标,神经外科医生在制定低级别和高级别神经胶质瘤的手术计划时,应根据术前影像学和患者的表现状态,在可行的情况下进行最大限度切除,并利用每个术中辅助手段将术后神经功能缺损降至最低。虽然手术入路和技术可能有所不同,但必须尽一切努力识别和保护功能皮质和皮质下区域。在这篇关于该领域现状的总结性陈述中,我们描述了有助于安全切除弥漫性神经胶质瘤的工具和技术,并强调了术中及术后管理策略,以最大限度地减少这些患者的并发症。此外,我们还讨论了手术切除如何通过促进生物学发现和改善辅助化疗和放疗的局部递送来超越细胞减灭术。